LDHA and B-cell chronic lymphocytic leukemia: In addition, NAMPTi was found to be effective in the following combinations: with Vorinostat for CLL and acute myeloid leukemia, with TRAIL for t-cell leukemia and CLL, with FX-11 for LDHA-dependent lymphomas, with Bortezomib for multiple myeloma, and with Rituxumab for B-cell lymphoma (Le et al., 2010; Zoppoli et al., 2010; Cea et al., 2011; Cagnetta et al., 2013; Nahimana et al., 2014).